和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02256 和誉-B

休市中 11-14 16:08:11

14.700

+0.060

+0.41%

最高15.000	最低14.100	成交量147.10万
今开14.640	昨收14.640	日振幅6.15%
总市值98.78亿	流通市值98.78亿	总股本6.72亿
成交额2,159万	换手率0.22%	流通股本6.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02256","market":"HK","secType":"STK","nameCN":"和誉-B","latestPrice":14.7,"timestamp":1763107691004,"preClose":14.64,"halted":0,"volume":1471000,"delay":0,"floatShares":672000000,"shares":672000000,"eps":0.048881598010259604,"marketStatus":"休市中","change":0.06,"latestTime":"11-14 16:08:11","open":14.64,"high":15,"low":14.1,"amount":21586847,"amplitude":0.061475,"askPrice":14.71,"askSize":11000,"bidPrice":14.7,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":0.24385610104150476,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763343000000},"marketStatusCode":7,"adr":0,"listingDate":1634054400000,"exchange":"SEHK","adjPreClose":14.64,"openAndCloseTimeList":[[1763083800000,1763092800000],[1763096400000,1763107200000]],"volumeRatio":0.6288,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02256/wiki","defaultTab":"wiki","newsList":[{"id":"2583653465","title":"每日卖空追踪 | 和誉-B 11月13日卖空量成交5.2万股，卖空比例为4.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583653465","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583653465?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:30","pubTimestamp":1763022631,"startTime":"0","endTime":"0","summary":"和誉-B北京时间11月13日，涨3.68%，卖空量成交5.2万股，较上一交易日减少96.68%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511131634099501d427&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511131634099501d427&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2476274720.SGD","LU2778985437.USD","02256","LU2488822045.USD","BK1161","LU2476274308.USD"],"gpt_icon":0},{"id":"2583565311","title":"和誉-B11月13日主力净流入50.9万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2583565311","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583565311?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:16","pubTimestamp":1763021760,"startTime":"0","endTime":"0","summary":"11月13日, 和誉-B股价涨3.68%，报收14.64元，成交金额1672.9万元，换手率0.17%，振幅5.17%，量比0.46。和誉-B今日主力资金净流入50.9万元，上一交易日主力净流出116.6万元。该股近5个交易日上涨0.20%，主力资金累计净流入78.1万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出1958.6万元，其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511131622509501ce08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511131622509501ce08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","LU2488822045.USD","LU2778985437.USD","BK1161","LU2476274720.SGD","LU2476274308.USD"],"gpt_icon":0},{"id":"2582361124","title":"每日卖空追踪 | 和誉-B 11月11日卖空量成交3.6万股，卖空比例为1.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582361124","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582361124?lang=zh_cn&edition=full","pubTime":"2025-11-11 16:30","pubTimestamp":1762849828,"startTime":"0","endTime":"0","summary":"和誉-B北京时间11月11日，跌2.1%，卖空量成交3.6万股，较上一交易日减少77.64%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111163358a49958cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111163358a49958cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2476274720.SGD","LU2488822045.USD","02256","LU2476274308.USD","LU2778985437.USD","BK1161"],"gpt_icon":0},{"id":"2582806503","title":"每日卖空追踪 | 和誉-B 11月10日卖空量成交9万股，卖空比例为5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582806503","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582806503?lang=zh_cn&edition=full","pubTime":"2025-11-10 16:30","pubTimestamp":1762763425,"startTime":"0","endTime":"0","summary":"和誉-B北京时间11月10日，涨0.92%，卖空量成交9万股，较上一交易日减少50%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110163410a496c5e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110163410a496c5e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","LU2488822045.USD","LU2476274720.SGD","BK1161","LU2476274308.USD","LU2778985437.USD"],"gpt_icon":0},{"id":"2581361588","title":"每日卖空追踪 | 和誉-B 11月07日卖空量成交7万股，卖空比例为5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581361588","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581361588?lang=zh_cn&edition=full","pubTime":"2025-11-07 16:30","pubTimestamp":1762504227,"startTime":"0","endTime":"0","summary":"和誉-B北京时间11月07日，跌3.34%，卖空量成交7万股，较上一交易日减少78.12%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251107163346a6e8271a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251107163346a6e8271a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2476274720.SGD","LU2488822045.USD","LU2476274308.USD","LU2778985437.USD","02256","BK1161"],"gpt_icon":0},{"id":"2581772385","title":"每日卖空追踪 | 和誉-B 11月05日卖空量成交17.3万股，卖空比例为12.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581772385","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581772385?lang=zh_cn&edition=full","pubTime":"2025-11-05 16:30","pubTimestamp":1762331428,"startTime":"0","endTime":"0","summary":"和誉-B北京时间11月05日，涨0.55%，卖空量成交17.3万股，较上一交易日减少34.22%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105163359a6e2aca0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105163359a6e2aca0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","02256","LU2778985437.USD","BK1161","LU2476274720.SGD","LU2476274308.USD"],"gpt_icon":0},{"id":"2581711472","title":"和誉-B11月04日遭主力抛售177.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581711472","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581711472?lang=zh_cn&edition=full","pubTime":"2025-11-04 16:15","pubTimestamp":1762244136,"startTime":"0","endTime":"0","summary":"11月04日, 和誉-B股价跌3.14%，报收14.50元，成交金额2962.9万元，换手率0.30%，振幅3.87%，量比0.73。和誉-B今日主力资金净流出177.7万元，连续3日净流出，上一交易日主力净流出460.1万元。该股近5个交易日下跌2.36%，主力资金累计净流出825.4万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出1958.3万元，其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104161830a6dfe6a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104161830a6dfe6a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2476274308.USD","LU2476274720.SGD","LU2778985437.USD","LU2488822045.USD","BK1161","02256"],"gpt_icon":0},{"id":"2580277022","title":"大行评级丨瑞银：首予和誉“买入”评级及目标价25.2港元 看好公司的差异化管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2580277022","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580277022?lang=zh_cn&edition=full","pubTime":"2025-11-04 12:07","pubTimestamp":1762229221,"startTime":"0","endTime":"0","summary":"瑞银发表报告指，首次覆盖和誉，予“买入”评级，目标价25.2港元。该行指，和誉是被低估的创新肿瘤药物公司，其研发管线中有12种临床阶段资产和10种已披露的临床前候选药物。和誉与默沙东达成6.055亿美元的pimicotinib全球使用权授权协议，展现了公司的研发能力。该行看好和誉的差异化管线。基于稳健的临床试验结果和对其研发能力的信心，该行对其核心资产pimicotinib和irpagratinib的风险经调整高峰销售预测分别为89亿和48亿元，分别高过市场预期41%和26%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251104/31765355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02256"],"gpt_icon":0},{"id":"2580210021","title":"每日卖空追踪 | 和誉-B 11月03日卖空量成交15万股，卖空比例为5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580210021","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580210021?lang=zh_cn&edition=full","pubTime":"2025-11-03 16:30","pubTimestamp":1762158627,"startTime":"0","endTime":"0","summary":"和誉-B北京时间11月03日，涨2.82%，卖空量成交15万股，较上一交易日减少47.37%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251103163344a484a6dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251103163344a484a6dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2580887230","title":"和誉-B(02256)完成口服小分子PD-L1抑制剂ABSK043联合戈来雷塞治疗NSCLC II期临床首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2580887230","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580887230?lang=zh_cn&edition=full","pubTime":"2025-11-03 08:13","pubTimestamp":1762128819,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，2025年11月3日，和誉医药宣布，其口服小分子PD-L1抑制剂ABSK043与上海艾力斯医药科技股份有限公司(艾力斯) KRAS G12C抑制剂戈来雷塞联合用于治疗携带KRAS G12C突变的非小细胞肺癌的II期临床研究已完成首例患者给药。本项开放标签II期临床研究，旨在评估ABSK043联合戈来雷塞治疗携带KRAS G12C突变的局部晚期或转移性NSCLC患者的安全性、耐受性及有效性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","LU2488822045.USD","PD","BK1161","02256","LU1169589451.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2579435695","title":"透过和誉-B(02256)研发日，看其打造FIC/BIC创新管线的深度与广度","url":"https://stock-news.laohu8.com/highlight/detail?id=2579435695","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579435695?lang=zh_cn&edition=full","pubTime":"2025-10-31 13:36","pubTimestamp":1761888965,"startTime":"0","endTime":"0","summary":"如今，这些成果都集中体现在公司10月30日召开的2025研发日活动中。加上此前的首付款，双方的BD合作已为和誉带来逾1.5亿美元现金。例如，口服小分子PD-L1抑制剂ABSK043在临床研究中展现出类抗体疗效和极佳的口服便利性，同时良好的安全性显示其具备克服多药联合治疗安全性风险的潜力。以上无一不在体现和誉在全球商业化和差异化原研创新方面的确定性，和誉有望通过管线内多个具备潜在FIC/BIC产","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02256","LU2488822045.USD"],"gpt_icon":0},{"id":"2579361436","title":"和誉-B盘中异动 股价大涨5.30%报14.700港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579361436","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579361436?lang=zh_cn&edition=full","pubTime":"2025-10-31 10:53","pubTimestamp":1761879224,"startTime":"0","endTime":"0","summary":"2025年10月31日早盘10时53分，和誉-B股票出现波动，股价大幅拉升5.30%。截至发稿，该股报14.700港元/股，成交量96.5万股，换手率0.14%，振幅6.52%。资金方面，该股资金流入863.55万港元，流出310.709万港元。和誉-B股票所在的生物技术行业中，整体涨幅为3.91%。该公司拥有两款核心候选产品ABSK011和 ABSK091,以及12款其他在研产品。消息层面，截至10时53分，《国元国际：和誉-B买入评级 目标价22.06港元》资讯为影响和誉-B的重要信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031105344a47efc26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031105344a47efc26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02256","LU2488822045.USD"],"gpt_icon":0},{"id":"2579443636","title":"每日卖空追踪 | 和誉-B 10月30日卖空量成交14.2万股，卖空比例为6.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579443636","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579443636?lang=zh_cn&edition=full","pubTime":"2025-10-30 16:30","pubTimestamp":1761813026,"startTime":"0","endTime":"0","summary":"和誉-B北京时间10月30日，跌2.92%，卖空量成交14.2万股，较上一交易日减少11.8%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510301635569749f7c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510301635569749f7c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2579467329","title":"国元国际：和誉-B(02256)买入评级 目标价22.06港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579467329","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579467329?lang=zh_cn&edition=full","pubTime":"2025-10-29 10:51","pubTimestamp":1761706273,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国元国际发布研报称，和誉-B是小分子创新药龙头。预计2025-27年收入分别为人民币6.50亿、6.80亿、7.30亿元，净利润分别为0.97亿、1.11亿、1.42亿元，根据DCF模型，目标价22.06港元，给予买入评级，较现价有48.5%的升幅。截至第73周，患者相对关节活动度较基线改善达23.9%。ABSK061等处于二期临床阶段，061在软骨发育不全症及多种癌症方面潜力大。于2025年6月完成注册性研究的首例患者给药。计划入组约141名患者。目前晚期肝癌病人缺乏有效的治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1361903.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256"],"gpt_icon":0},{"id":"2578621321","title":"每日卖空追踪 | 和誉-B 10月27日卖空量成交9.4万股，卖空比例为4.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578621321","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578621321?lang=zh_cn&edition=full","pubTime":"2025-10-27 16:30","pubTimestamp":1761553830,"startTime":"0","endTime":"0","summary":"和誉-B北京时间10月27日，涨4.72%，卖空量成交9.4万股，较上一交易日减少12.96%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251027163436a6d053e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251027163436a6d053e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2578667618","title":"和誉-B(02256.HK)盘中涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578667618","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578667618?lang=zh_cn&edition=full","pubTime":"2025-10-27 10:12","pubTimestamp":1761531174,"startTime":"0","endTime":"0","summary":"每经AI快讯，和誉-B(02256.HK)盘中涨超7%，截至发稿，涨6.06%，报15.03港元，成交额916.86万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510273545050147.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510273545050147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","02256","BK1161"],"gpt_icon":0},{"id":"2578662172","title":"港股异动 | 和誉-B(02256)盘中涨超7% 于2025年ESMO会议展示匹米替尼临床III期相关研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2578662172","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578662172?lang=zh_cn&edition=full","pubTime":"2025-10-27 10:01","pubTimestamp":1761530487,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B盘中涨超7%，截至发稿，涨6.06%，报15.03港元，成交额916.86万港元。目前，匹米替尼已被中国国家药品监督管理局药品审评中心纳入优先审评，用于需要系统性治疗的TGCT成人患者。匹米替尼还获得了NMPA授予的突破性疗法认定。在海外地区，匹米替尼也获得了美国食品药品监督管理局授予BTD，和获得欧洲药品管理局授予优先药品认定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1360187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","BK1161","02256","BK4134","III"],"gpt_icon":0},{"id":"2578766668","title":"和誉-B(02256)：ABK-CDK-1和ABK-SM2-1均表现出优异的临床前特性","url":"https://stock-news.laohu8.com/highlight/detail?id=2578766668","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578766668?lang=zh_cn&edition=full","pubTime":"2025-10-27 08:02","pubTimestamp":1761523374,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 公布，公司的附属公司上海和誉生物医药科技有限公司已于第37届AACR-NCI-EORTC国际分子靶标与癌症治疗大会上公布了两款管线项目—CDK4/2抑制剂ABK-CDK-1和SMARCA2 PROTAC降解剂ABK-SM2-1的最新临床前研究成果，两者均表现出优异的临床前特性。和誉医药开发的ABK-CDK-1是一种新型、选择性、可透过血脑屏障的 CDK4/2抑制剂，具有克服现有CDK4/6抑制剂局限性的潜力。ABK-SM2-1优异的临床前特性支持其推进临床前开发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1360135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02256","LU2488822045.USD"],"gpt_icon":0},{"id":"2577582571","title":"和誉-B10月23日遭主力抛售471.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577582571","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577582571?lang=zh_cn&edition=full","pubTime":"2025-10-23 16:15","pubTimestamp":1761207337,"startTime":"0","endTime":"0","summary":"10月23日, 和誉-B股价跌5.30%，报收14.47元，成交金额1.1亿元，换手率1.11%，振幅8.12%，量比3.34。和誉-B今日主力资金净流出471.0万元，连续3日净流出，上一交易日主力净流出125.5万元。该股近5个交易日下跌11.31%，主力资金累计净流出879.5万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出837.4万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023161846a6c999f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023161846a6c999f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","02256","BK1161"],"gpt_icon":0},{"id":"2577379211","title":"和誉-B盘中异动 大幅跳水5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577379211","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577379211?lang=zh_cn&edition=full","pubTime":"2025-10-23 10:03","pubTimestamp":1761185000,"startTime":"0","endTime":"0","summary":"2025年10月23日早盘10时03分，和誉-B股票出现波动，股价快速下跌5.04%。截至发稿，该股报14.510港元/股，成交量68.7万股，换手率0.10%，振幅4.91%。和誉-B股票所在的生物技术行业中，整体跌幅为1.81%。其相关个股中，永泰生物-B、维升药业-B、药捷安康-B涨幅较大，振幅较大的相关个股有荃信生物-B、轩竹生物-B、云康集团，振幅分别为12.52%、11.00%、10.58%。该公司拥有两款核心候选产品ABSK011和 ABSK091,以及12款其他在研产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023100320a46f873e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023100320a46f873e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbisko.com","stockEarnings":[{"period":"1week","weight":-0.0007},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.085},{"period":"6month","weight":0.7875},{"period":"1year","weight":2.2899},{"period":"ytd","weight":2.1826}],"compareEarnings":[{"period":"1week","weight":0.0222},{"period":"1month","weight":0.0641},{"period":"3month","weight":0.0713},{"period":"6month","weight":0.1597},{"period":"1year","weight":0.3657},{"period":"ytd","weight":0.3496}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和誉开曼有限责任公司是一家临床阶段生物制药公司。该公司致力于发现和开发创新差异化的小分子肿瘤疗法。该公司拥有两款核心候选产品ABSK011和 ABSK091，以及12款其他在研产品。ABSK011是一种强效且高选择性的成纤维细胞生长因子受体4(FGFR4) 小分子抑制剂。ABSK091 是一种分子靶向候选产品，也是 FGFR亚型 1、2和3的强效和选择性抑制剂。该公司的产品主要用于肝细胞癌(HCC)、尿路上皮癌(UC) 和胃癌(GC)。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.143011},{"month":2,"riseRate":0.75,"avgChangeRate":0.046576},{"month":3,"riseRate":0.5,"avgChangeRate":0.054417},{"month":4,"riseRate":0.25,"avgChangeRate":-0.010041},{"month":5,"riseRate":0.25,"avgChangeRate":0.029375},{"month":6,"riseRate":0.5,"avgChangeRate":0.006841},{"month":7,"riseRate":0.75,"avgChangeRate":0.047273},{"month":8,"riseRate":0.5,"avgChangeRate":0.114048},{"month":9,"riseRate":0.75,"avgChangeRate":0.043844},{"month":10,"riseRate":0.5,"avgChangeRate":-0.043137},{"month":11,"riseRate":0.8,"avgChangeRate":0.164649},{"month":12,"riseRate":0,"avgChangeRate":-0.093315}],"exchange":"SEHK","name":"和誉-B","nameEN":"ABBISKO-B"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.5","shortVersion":"4.35.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和誉-B,02256,和誉-B股票,和誉-B股票老虎,和誉-B股票老虎国际,和誉-B行情,和誉-B股票行情,和誉-B股价,和誉-B股市,和誉-B股票价格,和誉-B股票交易,和誉-B股票购买,和誉-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}